EMA con­sid­ers se­ri­ous eye con­di­tion a ‘very rare’ side ef­fect of semaglu­tide 

The Eu­ro­pean Med­i­cines Agency said Fri­day that the prod­uct in­for­ma­tion for No­vo Nordisk’s Ozem­pic and We­govy should be up­dat­ed to list a se­ri­ous eye con­di­tion …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER